GSK (GSK, $39.06) Chairman Philip Hampton To Step Down
After serving as chairman for more than three and a half years at GlaxoSmithKline Plc, Philip Hampton is resigning from his post.
The news comes a month after the announcement from GSK’s Chief Executive Emma Walmsley that the company will be split into two businesses — one for prescription drugs and vaccines, the other for over-the-counter products.
In December, it was announced that GSK and Pfizer would combine their consumer health businesses in an all-equity deal. GSK will own 68 percent of the joint venture. Estimated sales of the combined entity are 9.8 billion pounds ($12.7 billion).
“Following the announcement of our deal with Pfizer and the intended separation of the new consumer business, I believe this is the right moment to step down and allow a new Chair to oversee this process through to its conclusion over the next few years,” Hampton said in a statement.
Hampton had joined GSK at a time when the company was struggling with weak sales of its core respiratory drugs.
GSK said that it had started looking for a successor.
GSK in downward trend: price dove below 50-day moving average on June 15, 2026
GSK moved below its 50-day moving average on June 15, 2026 date and that indicates a change from an upward trend to a downward trend. In of 38 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 57 cases where GSK's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GSK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for GSK entered a downward trend on June 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where GSK's RSI Indicator exited the oversold zone, of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on June 11, 2026. You may want to consider a long position or call options on GSK as a result. In of 67 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for GSK just turned positive on May 19, 2026. Looking at past instances where GSK's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GSK advanced for three days, in of 326 cases, the price rose further within the following month. The odds of a continued upward trend are .
GSK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.363) is normal, around the industry mean (19.363). P/E Ratio (13.678) is within average values for comparable stocks, (26.309). Projected Growth (PEG Ratio) (19.381) is also within normal values, averaging (15.981). Dividend Yield (0.034) settles around the average of (0.031) among similar stocks. P/S Ratio (2.432) is also within normal values, averaging (3.935).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 66, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. GSK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of vaccines and other pharmaceutical products
Industry PharmaceuticalsMajor
Advertisement